Suven Pharma Targets USD 1 Bn Revenue by 2030

CDMO, Suven Pharmaceuticals, aims to reach USD 1 bn in revenue by 2030, by investing in new facilities to increase production capacity and strengthen its capabilities in drug development and manufacturing to support global pharmaceutical clients.

Focusing on specialized molecules and complex drug formulations, Suven plans to capitalize on growing demand in the CDMO sector through strategic partnerships, innovation, and operational efficiency to become a major player in the global pharmaceutical manufacturing market.

The following article originally appeared in NDTV Profit.

Suven Pharmaceuticals is on track to achieve its ambitious $1-billion revenue target by 2030, driven by the rapid growth of its contract development and manufacturing organisation or CDMO segment, according to the company's Executive Chairman Vivek Sharma. “If you look at large pharma companies or biotech, they are all looking for partners like us to accelerate their drug delivery as well as improve their cost margins. They are all under tremendous pressure to bring drugs to the market sooner. So as a key partner to the supply chain, we believe that the CDMO industry will continue to grow over the foreseeable future. Three key areas which we talk about as CDMO are the API, ADC, and Oligo," he said during a conversation with NDTV Profit.

For more, please find the original story source here.